selumetinib (AZD6244)
Jump to navigation
Jump to search
Contraindications
- KRAS mutant advanced non-small cell lung cancer
* does not provides survival advantage over docetaxel alone
Mechanism of action
- inhibits mek kinase-1 & mek kinase-2[2]
More general terms
References
- ↑ Janne PA, van den Heuvel MM, Barlesi F et al Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer. The SELECT-1 Randomized Clinical Trial. JAMA. 2017;317(18):1844-1853. May 9, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28492898 <Internet> http://jamanetwork.com/journals/jama/article-abstract/2625317
- ↑ 2.0 2.1 PubChem: 10127622